The Filing Desk

Syndax Pharmaceuticals vs Stoke Therapeutics

Syndax Pharmaceuticals SNDX · Stoke Therapeutics STOK · Pharmaceuticals

Stoke Therapeutics reported revenue of $184 million in fiscal 2025, about the same as Syndax Pharmaceuticals' $172 million in fiscal 2025. Syndax Pharmaceuticals' revenue grew 627.8% in its latest year, and Stoke Therapeutics' grew 404.5%. Syndax Pharmaceuticals had an operating margin of -158.4%, against -11.2% at Stoke Therapeutics. Free cash flow was −$323 million at Syndax Pharmaceuticals and $45 million at Stoke Therapeutics.

Side by side

Syndax PharmaceuticalsStoke Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$172M$184M
Revenue growth627.8%404.5%
Revenue growth a year, last 5 years158.3%—
Gross margin——
Operating margin−158.4%−11.2%
Net margin−165.6%−3.7%
Free cash flow−$323M$45M
Free cash flow margin−187.5%24.4%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count1.2%9.7%
Last close$9.45$26.68
P/E at the last close——
Insider trades, last 12 monthssold $2.7 millionsold $8.7 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Syndax PharmaceuticalsStoke Therapeutics
Operating margin
Percent of revenue
Syndax PharmaceuticalsStoke Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Syndax PharmaceuticalsStoke Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Syndax Pharmaceuticals and Stoke Therapeutics pages.